Milowsky, Matthew I <br/><br/>
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Dec 2014 
 - 3145-52 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2014.10.013  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Benzimidazoles--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasm Metastasis<br/>Quinolones--administration & dosage<br/>Receptor, Fibroblast Growth Factor, Type 3--genetics<br/>Treatment Outcome<br/>Urologic Neoplasms--drug therapy